Go or no go? Oncology decisions ahead for the FDA

Go or no go? Oncology decisions ahead for the FDA

Submitted by admin on January 27, 2021 - 11:55am
Source: 
EP Vantage
News Tags: 
FDA
cancer
oncology
Bristol-Myers Squibb
TG Therapeutics
Mallinckrodt
Sanofi
Regeneron
Sarepta Therapeutics
GSK
Oncopeptide
Headline: 
Go or no go? Oncology decisions ahead for the FDA
snippet: 

The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.

Do Not Allow Advertisers to Use My Personal information